A Study of Brenipatide in Adult Participants With Schizophrenia

Summary

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Schizophrenia

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 55 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Eli Lilly and Company

Last updated on ClinicalTrials.gov

October 7, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites